SMi’s 2nd Annual AI in Drug Discovery Conference

Conference: 15 – 16 March 2021
Virtual Conference: Online Access Only  
Website: 

Chaired by: Darren Green, Director of Molecular Design & Senior Fellow, GSK

Sponsored by: OpenEye Scientific Software

SMi is proud to present its 2nd Annual AI in Drug Discovery Conference, taking place on the 15-16 March 2021.

With the global Artificial Intelligence (AI) in Drug Discovery Market size expected to exceed $3,900 million by 2027, the conference agenda will encompass key drivers leading the way into a shorter, cheaper, and more successful R&D era. The conference will be a particular focus on case studies from leading pharma and biotech, as well as a close-up view on the paradigm shift from undruggable targets to ‘challenging to drug’. 
Furthermore the event will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases, and will highlight key case studies across these themes, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored in eye-opening detail

Event Hashtag: #SMiAIDrugDis

HIGHLIGHTS FOR 2021 INCLUDE:
• Discover the latest innovations in AI-based drug discovery platforms
• Engage in case study presentations from leading pharma and biotech companies on machine learning and improved drug discovery pipelines
• Understand how AI can be effectively implemented to enhance productivity
• Delve into best practices in data quality, curation, and validation
• Explore how AI is being used to unlock therapies that have evaded traditional drug discovery

KEY SPEAKERS INCLUDE
• Noor Shaker, CEO, Glamorous AI
• Maria Luisa Pineda, Co-Founder & CEO, Envisagenics
• Ed Addison, Co-founder, Chairman, and CEO, Cloud Pharmaceuticals
• Liling Warren, Director, Head of Translational Medicine Statistics, Teva Pharmaceuticals
• Lili Peng, Associate Director Scientific Ecosystem Analytics Lead, Biogen
• Mark De Pristo, CEO, BigHat Biosciences
• Philipe Moingeon, Head of Immuno-inflammation, Servier 
• Hugo Ceulemans, Scientific Director, Discovery Data Sciences, Janssen
• Peter Henstock, Machine Learning & AI Lead, Pfizer
• Naheed Kurji, CEO, Cyclica

WHO SHOULD ATTEND
CEOs, Presidents, Vice Presidents and Global Heads, Executive Directors, Vice President & Global head, Principal Scientists, Heads of Business Development, Directors of Pharma/Biotech firms.